1. Home
  2. J vs INSM Comparison

J vs INSM Comparison

Compare J & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jacobs Solutions Inc.

J

Jacobs Solutions Inc.

HOLD

Current Price

$135.62

Market Cap

17.5B

Sector

Industrials

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$197.05

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
J
INSM
Founded
1947
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.5B
41.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
J
INSM
Price
$135.62
$197.05
Analyst Decision
Buy
Strong Buy
Analyst Count
10
19
Target Price
$155.90
$180.94
AVG Volume (30 Days)
1.4M
2.8M
Earning Date
11-20-2025
10-30-2025
Dividend Yield
0.94%
N/A
EPS Growth
N/A
N/A
EPS
2.38
N/A
Revenue
$12,029,783,000.00
$447,022,000.00
Revenue This Year
N/A
$43.10
Revenue Next Year
$6.38
$128.25
P/E Ratio
$56.94
N/A
Revenue Growth
4.60
30.34
52 Week Low
$106.23
$60.40
52 Week High
$168.44
$212.75

Technical Indicators

Market Signals
Indicator
J
INSM
Relative Strength Index (RSI) 39.32 51.97
Support Level $132.50 $189.59
Resistance Level $143.16 $206.69
Average True Range (ATR) 3.29 6.40
MACD 0.47 -2.76
Stochastic Oscillator 41.82 30.20

Price Performance

Historical Comparison
J
INSM

About J Jacobs Solutions Inc.

Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: